Our results of early predictive, sensitive, nonspecific serum NGAL, although of clear statistical significance, will certainly need to be validated in a larger trial, including patients with preexisting chronic kidney disease and co morbid conditions that normally accumulate with impaired renal function. This evidence concerns the gene LCN2 and chronic kidney disease.